Related Experiment Video
Updated: May 22, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions
1Department of Hepatobiliary Surgery, JiuJiang City Key Laboratory of Cell Therapy, JiuJiang No.1 People's Hospital, Jiujiang, Jiangxi, China.
Abstract:
Tumors employ a range of strategies to evade detection and eradication by the host's immune system. These include downregulating antigen expression, altering antigen presentation processes, and inhibiting immune checkpoint pathways. etc. Adoptive Cell Therapy (ACT) represents a strategy that boosts anti-tumor immunity. This is achieved by amplifying or genetically engineering immune cells, which are either sourced from the patient or a donor, in a laboratory setting. Subsequently, these cells are reintroduced into the patient to bolster their immune response against cancer. ACT has successfully restored anti-tumor immune responses by amplifying the activity of T cells from patients or donors. This review focuses on the mechanisms underlying tumor escape, including alterations in tumor cell antigens, the immunosuppressive tumor microenvironment (TME), and modulation of immune checkpoint pathways. It further explores how ACT can avddress these factors to enhance therapeutic efficacy. Additionally, the review discusses the application of gene-editing technologies (such as CRISPR) in ACT, highlighting their potential to strengthen the anti-tumor capabilities of T cells. Looking forward, the personalized design of ACT, combined with immune checkpoint inhibitors and targeted therapies, is expected to significantly improve treatment outcomes, positioning this approach as a key strategy in the field of cancer immunotherapy.
Insights
Adoptive Cell Therapy (ACT) enhances anti-tumor immunity by engineering immune cells to combat cancer. This approach addresses tumor evasion strategies and holds promise for improved cancer immunotherapy outcomes.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumors evade immune detection through mechanisms like antigen downregulation and immune checkpoint modulation.
- The tumor microenvironment (TME) is often immunosuppressive, hindering effective anti-tumor responses.
Purpose of the Study:
- To review tumor immune evasion strategies.
- To explore Adoptive Cell Therapy (ACT) as a countermeasure.
- To discuss the role of gene editing and future directions in ACT for cancer immunotherapy.
Main Methods:
- Review of literature on tumor immune evasion mechanisms.
- Analysis of Adoptive Cell Therapy (ACT) principles and applications.
- Discussion of gene-editing technologies (e.g., CRISPR) in enhancing T cell function.
Main Results:
- ACT effectively restores anti-tumor immunity by amplifying or engineering immune cells.
- ACT can overcome specific tumor escape mechanisms.
- Gene editing shows potential to augment T cell anti-tumor capabilities.
Conclusions:
- ACT is a promising strategy to enhance anti-tumor immunity.
- Personalized ACT, combined with other therapies, is expected to improve cancer treatment outcomes.
- ACT represents a key advancement in cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:40Cell-mediated Immune Responses
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...